



May 9, 2013

Ratio Change

Name: Can-Fite Biopharma Ltd.**DR CUSIP: 13471N102****DR ISIN: US13471N1028****DR Ticker Symbol: CANFY****Ratio (DRs:Underlying Shares): 1:50**

BNY Mellon has been advised that Can-Fite Biopharma announced a nominal value change from NIS 0.01 to NIS 0.25, which will result in a 1 for 25 reverse split on its ordinary shares in Israel. As a result, Can-Fite Biopharma has instructed BNY Mellon, as Depositary to effect a ratio change on the ADR program as follows:

Old Ratio: 1 ADS: 50 Ordinary Shares**New Ratio: 1 ADS : 2 Ordinary Shares****Effective Date: May 13, 2013**

No exchange of ADR certificates is required. Any outstanding ADR certificates will automatically be deemed to conform to the new parameters of the ADR facility. ADR holders need not take any action in regards to this ratio change.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis

Vice President

+1 212 815-4245

Ravi.davis@bnymellon.com

London

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold

Vice President

+852 2 840 9717

joe.oakenfold@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and/ or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliated brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.